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abstract
PURPOSE In this nationwide registry study, we investigated socioeconomic and structural patterns in referral to
phase I cancer trials in a case-control study design.
METHODS Personal identification numbers on all Danish patients referred to the Danish Phase I Unit at Rig-
shospitalet from 2005 to 2016, and a control group matched on age, sex, type of cancer, year of diagnosis, and
time from diagnosis to referral ensured individual-level linkage between several registries. We examined the
association between nonclinical factors—indicators of socioeconomic position and distance to the Phase I
Unit—and referral using a conditional logistic regression analysis adjusted for several clinical factors. Asso-
ciation between nonclinical factors and enrollment once referred was examined with a Cox proportional hazards
regression analysis in an historical cohort study design.
RESULTS Complete data were available for 1,026 (84%) of 1,220 referred patients. Significantly decreased odds
for referral were identified for patients with long distance to the Phase I Unit compared with short distance
(adjusted odds ratio [OR], 0.35; 95% CI, 0.30 to 0.41), for less education (less than 9 years) compared with
more (more than 12 years; OR, 0.69; 95% CI, 0.56 to 0.91), and for belonging to the lowest income quintile
compared with the highest (OR, 0.78; 95% CI, 0.62 to 0.97). Medium education (9 to 12 years) compared with
more, being outside the workforce compared with being within, and living alone compared with living with a
partner were also negatively associated with referral. Among patients referred, 252 enrolled in a trial. Nonclinical
factors were not associated with enrollment.
CONCLUSION On the basis of individual long-term registry data from an unselected cohort, novel anticancer
therapies seem to be tested on a socially selected group of patients with cancer.
J Clin Oncol 37:1111-1119. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Recruitment to clinical trials is crucial for the devel-
opment of new cancer therapeutics. The purpose of
phase I trials is to define the toxicity profile,1 although
advances in cancer genomics with the detection of
biomarkers have further guided therapeutic strate-
gies.2 It is possible that the chance of benefitting from
phase I trials for patients with cancer with advanced
progressive disease has increased as a result of a
personalized approach that is based on genomic
expression.3
It is well known that differences in clinical and non-
clinical factors are associated with the recruitment of
patients to cancer trials. Selection into trials is attrib-
utable to higher recruitment rates of patients at
younger age, men, non-Hispanic whites, patients with
health insurance, high income, and residence in ur-
ban areas4-8; however, the literature on recruitment
specifically to phase I cancer trials is limited. Studies
from the United States demonstrate that participants in
phase I trials are well educated and have high
income.9-11 Although these studies were conducted
without a comparison group, results suggest that pa-
tients with higher socioeconomic position (SEP) are
over-represented in phase I trials.
To explore whether improved strategies in phase I trials
benefit a selected population, we investigated if, in
Denmark, nonclinical factors are associated with dif-
ferences in referral pattern to phase I trials, hypoth-
esizing that low SEP and long distance to phase I unit
were, in fact, significant barriers for referral, although
not for enrollment once referred.
METHODS
Study Design
Our study investigated the association of nonclinical
factors with referral as primary outcome in a matched
case-control design. Cases were the unselected cohort
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of all 1,220 patients referred since the establishment of the
Danish Phase I Unit, from December 1, 2005, to April 30,
2016. We investigated the association of nonclinical factors
with enrollment as a secondary outcome in an historical
cohort design among referred patients only, with death as
competing risk. SEP variables were selected to cover dif-
ferent aspects of social resources: ability to perceive and
act on information (education), material resources (work-
force and income), and social support (cohabitation and
children living at home).12,13 Distance to the Phase I Unit
was included, although it is not a typical SEP factor, as it
represents a relevant structural challenge in a country with
only one phase I unit. Covariables covered demographic
and clinical factors that were considered to be likely to
confound—age, sex, cancer type, and year of diagnosis—
or mediate—presence or absence of metastases or phys-
ical or mental comorbidity—the association between
nonclinical factors and referral.
Setting
In Denmark, the Phase I Unit at the Department of On-
cology, Rigshospitalet, is the only dedicated unit estab-
lished with the purpose of conducting phase I cancer trials
on the basis of next-generation sequencing since 2013,14
whereas phase II and III trials are conducted at several
departments nationwide. Patients from all over the country
are referred by local hospital-based oncologists. No private
oncologic services are offered to residents of the country.
Study Population
From the electronic patient administrative system at the
hospital, we obtained baseline data on referral diagnosis,
date of referral, and the national personal 10-digit identi-
fication number (PIN).
Danish Civil Registration System
Since 1968, all residents of Denmark have been recorded
in the Danish Civil Registration System and assigned a PIN
that encodes sex and date of birth. The PIN enables the
linkage between all national registries and administrative
databases.15,16 From this registry, we obtained data on vital
status, migrations, cohabitation (living alone or with a
partner), children living at home (yes or no), and distance to
the Phase I Unit for the year of index date (referral/
matching). Distance to the Phase I Unit followed the five
administrative geographic regions of Denmark with cate-
gorization as short distance (same region as the Unit,
driving distances within 30 miles), medium (neighboring
region, distances within 120 miles), or far (remaining three
regions, distances within 330 miles).
Danish Cancer Registry
Since 1943, detailed information on all patients with cancer
has been registered in the Danish Cancer Registry (DCR),
the oldest nationwide, population-based cancer registry in
the world.17 FromDCR, we obtained information on the type
of cancer, date of diagnosis, presence or absence of
metastases, and the number of other cancer diseases at the
time of diagnosis (zero, one, or two or more). On the basis of
International Statistical Classification of Diseases, Tenth
Revision (ICD-10) codes, we created 14 diagnostic groups
for adjustments in analyses—buccal cavity and pharynx
(ICD-10 C00-C14), digestive organs (C15-C26), respiratory
system and intrathoracic organs (C30-C39), bones and
articular cartilage (C40-C41), skin (C43, C460), meso-
thelium and connective tissue (C45-C49), breast (C50),
female genitals (C51-C58), male genitals (C60-C63), uri-
nary tract (C64-C68), CNS (C69-C72, C751-C752), en-
docrine glands (C73-C74, C750, C754-759), ill-defined
cancer (C76-C80), and lymphatic and hematopoietic tissue
(C81-C96).
Statistics Denmark
Since 1850, Statistics Denmark has produced statistics on
all people resident in Denmark. The comprehensive col-
lection of data now includes such information as education
(since 197417) and income (since 197018). From here, we
obtained information on the following: highest attained
educational level, categorized as less education (less than
9 years, elementary and junior high school), medium edu-
cation (9 to 12 years, high school or vocational education),
andmore education (more than 12 years, higher education);
affiliation to work market categorized as within (employed,
unemployed, leave, or reduced work ability) and outside
(early retirement as a result of disability, pensioners, and
students); and disposable income, which was divided into
quintiles on the basis of yearly income after taxes compared
with the Danish population of the same age, sex, and year.
Danish National Patient Registry
Since 1978, the Danish National Patient Registry has
stored nationwide information on patients’ hospital ad-
missions: date of admission, diagnosis, treatments, and
operations on the basis of on patients’ somatic admissions.
In 1994, outpatient visits and ICD-10 codes were added,
and psychiatric admissions were included beginning in
1995.19,20 Comorbidity was obtained from this registry and
measured as the Charlson comorbidity index21 on the basis
of diagnoses from somatic hospitalizations or outpatient
contacts in a 10-year period before the index date (score of
0, 1, or 2 or more).
Danish National Prescription Registry
From 1995, all prescribed medication dispensed at Danish
pharmacies has been registered with detailed information
on type, strength, and number of units.22,23 We obtained
data on psychological burden, measured as at least two
prescriptions or more for either antidepressants (N06A) or
anxiolytics (N05BA) for a 10-year period up to the index
date (yes or no).
Selection of Controls
For each patient-case, we identified all matching controls
on age (year of birth 6 3 years), sex, type of cancer
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(diagnostic groups on the basis of ICD-10 coding), and year
of diagnosis (6 1 year) from the DCR. Furthermore, we
ensured that eligible controls were alive at the date of re-
ferral of the patient. Patients could be controls for others
before their own referral, and the same person could act as
a control for several patients.
Congruence between patients’ referral diagnosis and the
diagnosis in the DCR was necessary for the extraction of
clinical data. We excluded 77 patients who lacked con-
sistency between the two diagnoses or for whom there was
no registry diagnosis. Five patients who were referred with
an advanced nonmelanoma skin cancer were likewise
excluded as the rarity of the disease presentation made
these patients incomparable with those with a non-
malignant disease presentation. Seven patients who were
not living in Denmark at the time of diagnosis were also
excluded. Bo matching controls existed for 24 patients.
This led to the exclusion of the rarest cases of cancer,
leaving a total of 1,107 patients (91%) who were eligible for
matching.
We matched patients individually, allowing for an indefinite
number of controls to avoid the exclusion of rare cases. The
total number of controls was thus 241,226, with a median
of 87 (range one to 2,805) controls per case.
Complete data on all variables and covariables were
available for 1,026 patients, thereby excluding 81 patients
(7%; Fig 1).
Statistical Analysis
To evaluate the primary outcome, we estimated odds ratios
(ORs) with 95% CIs for referral for each nonclinical factor
separately using conditional logistic regression, thereby
accounting for the different numbers of controls. We
studied three models: an unadjusted Model 0, which in-
cluded no covariables, except the exposure of interest;
Model 1, which also included mediators (the presence or
absence of metastases, number of cancers, comorbidity,
and psychological burden); and Model 2, which also in-
cluded nonclinical factors. Furthermore, we tested for the
effect modification by sex, age group, presence or absence
of metastases, year of referral, and distance to the Phase I
Unit, respectively, using likelihood ratio tests. In the
presence of a significant effect modification, we conducted
stratified analyses to assess ORs for individual groups.
For the secondary outcome, we applied Cox proportional
hazards regression models to estimate hazard ratios (HRs)
with 95% CIs for enrollment among referred patients for
each nonclinical factor separately. The start of follow-up
was date of referral. The end of follow-up was defined as
either the date of inclusion in the first trial, the date of death,
or 2 years after referral, whichever came first. We studied
three models: an unadjusted Model 0; a Model 1 adjusted
for confounders (age and year of referral modulated with a
polynomic spline, and sex); and a Model 2 adjusted for
possible mediators (number of cancers, presence or ab-
sence of metastases, comorbidity, and psychological
burden). We tested the proportional hazard assumption on
the basis of Schoenfeld residuals. Violations were found for
the variable diagnostic groups and analyses were thus
stratified on this variable. Furthermore, violations were
found for the variables, children living at home and distance
to the Phase I Unit, and we consequently divided the time
Incomplete data in registries 
(n = 81)
No diagnosis in DCR;
no matching controls in DCR
(n = 113)
Patients
(n = 1,107)
Analyzed patient-cases
(n = 1,026)
Analyzed controls
(n = 221,676)
Matching controls
(N = 241,226)
Patients
Excluded because of
incomplete data on the
matched patient-case
(n = 757)
Incomplete data in registries 
(n = 18,793)
Referred patients
 (N = 1,220)
Controls
FIG 1. Flow diagram of the study pop-
ulation of patients and controls. Matching
criteria included the following: age, sex,
type of cancer, year of diagnosis, and
days from diagnosis to index date (re-
ferral/matching). DCR, Danish Cancer
Registry.
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scale at 30 days (30 days or less andmore than 30 days) on
the basis of the visual inspection of the residuals. Analyses
were based on 1,026 complete cases (84% of 1,220) and
221,676 controls (92%) and carried out using R software
version 3.4.224 and relevant packages.25-32
Ethics and Data Protection
This registry study was conducted with approval from The
Danish Data Protection Agency (file number 2015-41-
4445) and The Danish Patient Safety Authority (file number
3-3013-1400/1).
Reporting of the study follows the Strengthening the
Reporting of Observational Studies in Epidemiology
statement.33
RESULTS
Descriptive Statistics
Patient characteristics according to demographic and
clinical covariables are listed in Table 1 and Appendix
Figure A1(online only) for the distribution of cancer types.
Primary Outcome
Long distance compared with short distance to the Phase I
Unit significantly decreased the likelihood for referral
(Model 2: OR, 0.35; 95% CI, 0.30 to 0.41), as did less
education compared with more (OR, 0.69; 95% CI, 0.56 to
0.84), as well as belonging to the lowest income group
compared with the highest (OR, 0.78; 95% CI, 0.62 to
0.97). Furthermore, ORs for referral were significantly
decreased for patients outside compared with those within
the workforce (OR, 0.76; 95% CI, 0.63 to 0.91) and for
patients with medium education compared with more
education (OR, 0.77; 95% CI, 0.67 to 0.90), as well as for
individuals living alone compared with living with a partner
(OR, 0.83; 95% CI, 0.72 to 0.97; Fig 2). Adjustments for
covariables did not change the significance level and only
resulted in slight changes in estimates in Model 1, in-
dicating that the mediators explained only part of the effect
of the nonclinical factors (Fig 2). Results of effect modifi-
cation tests and stratified analyses are listed in Appendix
Tables A1-A7 (online only).
Secondary Outcomes
A total of 252 patients who were referred to the Phase I Unit
were subsequently enrolled in at least one trial, among
whom data were complete for 197 (78%). The Cox pro-
portional hazards regression analysis demonstrated that
once the patients had been referred, nonclinical factors
were not associated with the hazard of enrollment. Al-
though they were based on a small number of events, time-
split analyses suggested variations over time. Therefore, no
children living at home compared with children living at
home increased the hazard of enrollment within the first
30 days after referral (HR, 2.02; 95% CI, 1.07 to 3.82);
however, this variable more than 30 days after referral did
not affect referral. Furthermore, long distance compared
TABLE 1. Characteristics of Patients Referred to the Danish Phase I Unit and
Matching Controls, Denmark, 2005 to 2016 (n 5 1,107 and n 5 241,226,
respectively)
Characteristic Patients Controls
No. of patients 1,107 (100) 241,226 (100)
Sex
Male 603 (54) 148,853 (62)
Female 504 (46) 92,373 (38)
Age, years
Median (IQR) 59 (51-65) 64 (59-68)
, 45 165 (15) 9,991 (4)
45-64 655 (59) 131,330 (54)
$ 65 287 (26) 99,905 (41)
Year of diagnosis
# 2000 45 (4) 6,554 (3)
2001-2005 215 (19) 43,745 (18)
2006-2010 452 (41) 103,955 (43)
2011-2016 395 (36) 86,972 (36)
Time from diagnosis to index
date, years
Median (IQR) 2.01 (1.08-3.63) 2.41 (1.28-4.08)
, 1 255 (23) 47,171 (20)
1-2 484 (44) 101,186 (42)
3-4 191 (17) 47,458 (20)
$ 5 177 (16) 45,411 (19)
No. of other tumors
0 938 (85) 199,252 (83)
1 146 (13) 36,201 (15)
2 23 (2) 5,773 (2)
Distant metastases
M0 471 (43) 166,967 (69)
M1 478 (43) 28,723 (12)
Mx 102 (9) 41,903 (17)
Missing information 56 (5) 3,633 (2)
Prescription
No 761 (69) 172,646 (72)
Yes 346 (31) 68,580 (28)
Charlson comorbidity index
0 816 (74) 164,274 (68)
1 218 (20) 49,944 (21)
2 73 (7) 27,008 (11)
NOTE. Data are given as No. (%), unless otherwise noted. The distribution for
each variable is not comparable between patients and controls because of the
various number of controls per patient. The number of tumors includes
nonmalignant tumors. The index date is the date of referral (patients) or matching
(controls). Prescriptions are for a 10-year period up to the index date.
Abbreviation: IQR, interquartile range.
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with short distance from the Phase I Unit decreased time to
enrollment within the first 30 days after referral (HR, 0.55;
95% CI, 0.31 to 0.95), whereas time to enrollment was
increased more than 30 days after referral (HR, 1.86; 95%
CI, 1.15 to 3.01; Fig 3). Results could not be explained by
mediators (Appendix Table A8, online only).
DISCUSSION
Across all nonclinical factors analyzed, with the exception
of children living at home, we observed a consistent pattern
of lower odds for referral to the national Phase I Unit with
low SEP and long distance to the Phase I Unit. The like-
lihood for enrollment once referred seemed to differ over
time after referral for the variables, children living at home
and distance to the Phase I Unit. Because of the small
numbers of events as a consequence of the time split, firm
conclusions cannot be reached with regard to the effect of
these variables. For the remaining variables, we did not find
that nonclinical factors influenced enrollment.
The main strength of our study is the ability to compare the
entire, unselected, nationwide cohort of previously referred
patients with a closely matched control group of patients
with cancer on a number of specific individual data. In-
clusion of several demographic and clinical factors reduced
the likelihood that our results can be explained by patient
characteristics. Our analyses were based on comprehen-
sive long-term registry data with individual-level linkage
between administrative registries established years before
Long distance to the phase I Unit
Medium distance to the phase I Unit
Short distance to the phase I Unit
No children living at home
Children living at home
Living alone
Living with partner
Income quintile 1 (lowest)
Income quintile 2
Income quintile 3
Income quintile 4
Income quintile 5 (highest)
Outside workforce
Within workforce
Less education
Medium education
More education
0.4 0.6 0.8 1.0 1.2 1.4
OR For Referral
304 (29.6)
286 (27.9)
436 (42.5)
820 (79.9)
206 (20.1)
270 (26.3)
756 (73.7)
147 (14.3)
190 (18.5)
221 (21.5)
241 (23.5)
227 (22.1)
325 (31.7)
701 (68.3)
182 (17.7)
514 (50.1)
330 (32.2)
1,026
Patients
122,742 (55.4)
37,781 (17.0)
61,153 (27.6)
203,759 (91.9)
17,917 ( 8.1)
60,514 (27.3)
161,162 (72.7)
41,987 (18.9)
45,022 (20.3)
45,710 (20.6)
45,836 (20.7)
43,121 (19.5)
109,388 (49.3)
112,288 (50.7)
51,274 (23.1)
115,832 (52.3)
54,570 (24.6)
221,676
Controls
0.35 (0.30 to 0.40)
0.34 (0.29 to 0.40)
0.35 (0.30 to 0.41)
1.10 (0.95 to 1.29)
1.13 (0.96 to 1.32)
1.16 (0.99 to 1.36)
1 (ref)
0.87 (0.71 to 1.06)
0.90 (0.74 to 1.11)
0.99 (0.80 to 1.22)
1 (ref)
0.82 (0.71 to 0.95)
0.85 (0.74 to 0.99)
0.83 (0.72 to 0.97)
1 (ref)
0.60 (0.49 to 0.74)
0.60 (0.48 to 0.74)
0.78 (0.62 to 0.97)
0.76 (0.62 to 0.92)
0.74 (0.61 to 0.91)
0.92 (0.75 to 1.13)
0.88 (0.73 to 1.07)
0.83 (0.68 to 1.01)
0.93 (0.77 to 1.14)
1.03 (0.85 to 1.24)
0.97 (0.81 to 1.17)
0.95 (0.79 to 1.15)
1 (ref)
0.63 (0.53 to 0.74)
0.67 (0.56 to 0.80)
0.76 (0.63 to 0.91)
1 (ref)
0.55 (0.45 to 0.67)
0.57 (0.47 to 0.69)
0.69 (0.56 to 0.84)
0.71 (0.61 to 0.82)
0.72 (0.62 to 0.83)
0.77 (0.67 to 0.90)
1 (ref)
OR (95% CI)
FIG 2. Odds ratios (ORs) with 95%CIs for referral to the Danish Phase I Unit (n = 1,026 referred patients and n = 221,676 controls), Denmark, 2005 to 2016,
by socioeconomic characteristics. Light blue, reference; red, Model 0, unadjusted model, confounders included by method; teal, Model 1, adjusted for the
number of cancers and presence or absence of metastases at diagnosis, as well as for psychological burden and comorbidity 10 years before referral
(mediators); dark orange, Model 2, adjusted for mediators and mutually for the socioeconomic position variables and distance to the Phase I Unit. Less
education is defined as less than 9 years, elementary and junior high school. Medium education is defined as 9 to 12 years, high school or vocational
education. More education is defined as more than 12 years, higher education. Ref, reference.
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the conception of our hypothesis and were thus in-
dependent of the hypothesis being tested and free of the
recall bias that could potentially compromise results that
are based on self-reported data.
Results from registry data involve some limitations. We had
to exclude 113 (9%) of 1,220 total patients beforematching
as there was no pattern in referral diagnosis for these
patents, which was interpreted as unsystematic missing
data. The remaining exclusion of 29 patients (2%) without
matching controls was a result of rare cancer diseases,
meaning that they were systematic and with potential in-
fluence on the generalizability of this study. Furthermore, as
phase I trials include patients with an advanced can-
cer disease and Eastern Cooperative Oncology Group
performance status (PS)34 of 0 to 1, the presence or ab-
sence of metastases and PS for patients at referral were
known. Controls may not have experienced a relapse, but,
conversely, they could have had worse PS than patients at
the index date. We addressed this by ensuring that controls
were still alive at the time of the referral of the appertaining
case.
Our findings of differences in access to health care services
are in line with a registry study from the United Kingdom of
430 patients who were referred to a National Healthcare
Service phase I trial compared with the general cancer
population.35 On the basis of a deprivation index, the most
deprived patients had roughly one half the chance (OR,
0.53; 95% CI, 0.38 to 0.74) compared with the least
Long distance the Phase I Unit, after 30 days
Medium distance to the Phase I Unit, after 30 days
Short distance to the Phase I Unit, after 30 days
Long distance the Phase I Unit, before 30 days
Medium distance to the Phase I Unit, before 30 days
Short distance to the Phase I Unit, before 30 days
No children living at home, after 30 days
Children living at home, after 30 days
No children living at home, before 30 days
Children living at home, before 30 days
Living alone
Living with partner
Income quintile 1 (lowest)
Income quintile 2
Income quintile 3
Income quintile 4
Income quintile 5 (highest)
Outside workforce
Within workforce
Less education
Medium education
More education
0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4
HR For Enrollment
52,974
86,780
31,672
117,200
54,226
36,601
41,195
35,236
34,227
24,167
124,013
47,413
5,833
22,890
31,508
137,385
12,058
8,048
8,617
77,592
49,610
41,691
Person Days
55
102
40
141
56
47
43
44
37
26
145
52
13
74
27
83
41
25
21
34
35
41
Events
2.01 (1.28 to 3.18)
1.66 (1.04 to 2.64)
1.86 (1.15 to 3.01)
1.59 (0.99 to 2.55)
1.55 (0.96 to 2.49)
1.65 (1.03 to 2.67)
1 (ref)
0.71 (0.42 to 1.21)
0.59 (0.34 to 1.00)
0.55 (0.31 to 0.95)
0.91 (0.55 to 1.50)
0.85 (0.52 to 1.40)
0.80 (0.48 to 1.35)
1 (ref)
0.77 (0.50 to 1.19)
1.01 (0.62 to 1.64)
0.96 (0.58 to 1.59)
1 (ref)
1.45 (0.81 to 2.62)
1.95 (1.04 to 3.65)
2.02 (1.07 to 3.82)
1 (ref)
1.01 (0.74 to 1.39)
1.00 (0.72 to 1.37)
0.97 (0.70 to 1.34)
1 (ref)
0.85 (0.53 to 1.38)
0.91 (0.56 to 1.48)
0.88 (0.53 to 1.44)
0.91 (0.59 to 1.39)
0.99 (0.64 to 1.52)
0.96 (0.62 to 1.50)
0.95 (0.63 to 1.43)
0.97 (0.64 to 1.46)
0.96 (0.63 to 1.46)
0.83 (0.55 to 1.25)
0.87 (0.58 to 1.33)
0.91 (0.59 to 1.38)
1 (ref)
0.85 (0.63 to 1.16)
1.19 (0.81 to 1.74)
1.21 (0.81 to 1.80)
1 (ref)
1.34 (0.89 to 2.02)
1.43 (0.94 to 2.19)
1.41 (0.91 to 2.20)
1.22 (0.88 to 1.69)
1.19 (0.86 to 1.66)
1.15 (0.83 to 1.61)
1 (ref)
HR (95% CI)
FIG 3. Hazard ratios (HRs) with 95% CIs for enrollment in phase I trials (n = 197 enrolled patients and n = 1,026 referred patients), Denmark, 2005 to 2016,
by socioeconomic characteristics. Light blue, reference; red, Model 0, unadjusted analysis; teal, Model 1, adjusted for age, sex, and year of referral
(confounders); dark orange, Model 2, adjusted for confounders and the number of cancers, cancer type, comorbidity, and psychological burden. Less
education is defined as less than 9 years, elementary and junior high school. Medium education is defined as 9 to 12 years, high school or vocational
education. More education is defined as more than 12 years, higher education. Without the time split, the estimate for no children living at home compared
with children living at homewasHR, 1.31 (95%CI, 0.86 to 1.98) and the estimate for distance to the Danish Phase I Unit was HR, 1.19 (95%CI, 0.84 to 1.68)
for medium distance compared with short distance and HR, 1.08 (95% CI, 0.75 to 1.55) for long distance compared with short distance. Ref, reference.
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deprived patients of being referred to a phase I trial. This
study identifies referral as the crucial point for a selection
that is based on SEP. Once referred, retrospective chart
reviews of 667 Canadian patients and 167 patients from the
United Kingdom did, in fact, suggest that the obstacles for
trial entry were related to clinical factors—protocol criteria
and individual clinical factors.36,37 On the basis of our
findings, selection by nonclinical factors seems to occur at
referral.
Our results could not be explained by clinical covariables.
Missing information on PS for controls could cause residual
mediation. An association between low PS and more ed-
ucation, as has been demonstrated among 6,234 patients
with non-Hodgkin lymphoma,38 would cause an over-
estimation of the association between nonclinical factors
and referral if controls had worse PS than did patient-cases.
Distance to the Phase I Unit may reflect both structural
challenges and differences in SEP across regions. In testing
for effect modification, distance did not affect the impact of
most SEP variables. Distance to the Phase I Unit was
identified as a reason for declining entry in a trial in a study
of 267 US patients, of whom 37 refused trial offers.39
However, in a retrospective chart review of 365 patients
and in a questionnaire survey of 106 patients, distance to
the hospital did not affect trial entry once patients had been
referred.40 This suggests that considerations of travel time
take place before referral. Although cautious interpretation
should be made because of the low number of events, we
found that long distance promotes enrollment more than
30 days after enrollment. Given the risk of rapid de-
terioration, this finding may be explained by better health
among referred patients with long distance to the Phase I
Unit. This is in line with an historical cohort study of 110
patients who participated in phase II trials in which patients
who lived more than 15 miles from the hospital had one
third the hazard of death.41
The presented association between nonclinical factors and
referral is assumed to be mediated by factors related to the
referring oncologists and patients (Appendix Fig A2, online
only). Referring oncologists may have contributed to the
skewed selection. In a cross-sectional study from the
United States that included 405 women with breast cancer,
young age, being non-Hispanic white, additional educa-
tion, and higher income were associated with better
communication between physician and patient,42 although
methodologic limitations do not allow solid conclusions.
Whether our findings reflect actual disparities43 cannot be
determined within this study design. As a consequence,
improved strategies in phase I trials do not benefit an
unselected population.
Because of the exclusion of the rarest cases—2% of the
entire patient population—as a result of the lack of
matching controls, our results cannot be generalized to the
complete population of patients referred to a phase I unit.
The current study demonstrates differences in referral
according to SEP and distance to a phase I unit in a country
with universal and publicly funded health care. As such
selection may be even more pronounced when health care
is based on governmental or private insurance or there is no
insurance at all, we expect our results to be relevant also in
countries with these health care conditions.
In conclusion, despite every Danish resident’s access to
universal, tax-funded, income-independent health care,
low SEP and long distance to the Danish Phase I Unit is a
barrier for referral. We find it important to draw attention to
the fact that the development of new anticancer therapies
seems to rely on a socially selected group of patients with
cancer, not only in terms of clinical factors but also social
characteristics. Our findings are of relevance in relation to
drug development, especially when applying findings from
experimental trials to the entire population of patients with
cancer.
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FIG A1. Distribution of cancer types among patients who were referred to the Danish Phase I Unit (n = 1,107), Denmark, 2005 to 2016.
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FIG A2. Hypothetical model of relationships between socioeconomic position, demographic and clinical
factors, and nonclinical factors—physician related and patient related—on referral to a phase I unit. Matching
variables are written in bold.
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TABLE A5. ORs With 95% CIs For Referral to the Phase I Unit, Denmark, 2005 to 2016, in a Subgroup Analysis of Distance to the Phase I Unit by Referral
Year (n 5 141,544 patients referred before 2014 and n 5 89,270 referred from 2014 to 2016)
Distance to the Phase I Unit
Referral Before 2014,
No. (%)
Referral Before 2014,
OR (95% CI)
Referral Since 2014,
No. (%)
Referral Since 2014,
OR (95% CI)
Short 39,721 (28.1) 1 (ref) 24,191 (27.1) 1 (ref)
Medium 24,333 (17.2) 1.19 (0.99 to 1.44) 15,088 (16.9) 1.06 (0.79 to 1.42)
Long 77,490 (54.7) 0.23 (0.18 to 0.28) 49,991 (56.0) 0.64 (0.50 to 0.81)
Abbreviations: OR, odds ratio; ref, reference.
TABLE A2. ORs With 95% CIs For Referral to the Phase I Unit, Denmark, 2005 to 2016, in a Subgroup Analysis of Distance to the Phase I Unit by Sex
(n 5 142,458 males and n 5 88,356 females)
Distance to the Phase I Unit Male, No. (%) Male, OR (95% CI) Female, No. (%) Female, OR (95% CI)
Short 39,394 (27.7) 1 (ref) 24,518 (27.7) 1 (ref)
Medium 24,875 (17.5) 1.31 (1.06 to 1.62) 14,546 (16.5) 0.98 (0.77 to 1.25)
Long 78,189 (54.9) 0.31 (0.25 to 0.39) 49,292 (55.8) 0.40 (0.32 to 0.50)
Abbreviations: OR, odds ratio; ref, reference.
TABLE A4. ORs With 95% CIs For Referral to the Phase I Unit, Denmark, 2005 to 2016, in a Subgroup Analysis of Income by Referral Year (n 5 141,544
patients referred before 2014 and n 5 89,270 referred from 2014 to 2016)
Income Quintile Referral Before 2014, No. (%) Referral Before 2014, OR (95% CI) Referral Since 2014, No. (%) Referral Since 2014, OR (95% CI)
5 (highest) 27,910 (19.7) 1 (ref) 17,043 (19.1) 1 (ref)
4 29,202 (20.6) 0.94 (0.73 to 1.20) 18,734 (21.0) 0.98 (0.72 to 1.31)
3 29,089 (20.6) 1.00 (0.78 to 1.29) 18,601 (20.8) 0.85 (0.62 to 1.16)
2 28,656 (20.2) 1.15 (0.89 to 1.49) 18,097 (20.3) 0.61 (0.43 to 0.89)
1 (lowest) 26,687 (18.9) 0.84 (0.63 to 1.11) 16,795 (18.8) 0.70 (0.49 to 1.02)
Abbreviations: OR, odds ratio; ref, reference.
TABLE A3. ORs With 95% CIs For Referral to the Phase I Unit, Denmark, 2005 to 2016, in a Subgroup Analysis of Distance to the Phase I Unit by
Age Categories (n 5 9,536 patients , 45 years, n 5 126,057 age 45 to 64 years, and n 5 95,221 $ 65 years of age)
Distance to the
Phase I Unit
Age < 45 Years,
No. (%)
Age < 45 Years, OR
(95% CI)
Age 45-64 Years,
No. (%)
Age 45-64 Years, OR
(95% CI)
Age ‡ 65 Years,
No. (%)
Age ‡ 65 Years, OR
(95% CI)
Short 3,071 (32.2) 1 (ref) 34,777 (27.6) 1 (ref) 26,064 (27.4) 1 (ref)
Medium 1,396 (14.6) 1.06 (0.62 to 1.81) 21,304 (16.9) 1.29 (1.06 to 1.58) 16,721 (17.6) 0.89 (0.66 to 1.21)
Long 5,069 (53.2) 0.67 (0.44 to 1.01) 69,976 (55.5) 0.37 (0.30 to 0.45) 52,436 (55.1) 0.21 (0.15 to 0.30)
Abbreviations: OR, odds ratio; ref, reference.
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TABLE A6. ORs With 95% CIs For Referral to the Phase I Unit, Denmark, 2005 to 2016, in a Subgroup Analysis of Workforce by Distance to the Phase I Unit
(n 5 63,912 patients with short distance, n 5 39,421 patients with medium distance, and n 5 127,481 patients with long distance to Phase I Unit)
Workforce
Participation
Short Distance to
the Phase I Unit,
No. (%)
Short Distance to the
Phase I Unit, OR
(95% CI)
Medium Distance to
the Phase I Unit,
No. (%)
Medium Distance to the
Phase I Unit, OR
(95% CI)
Long Distance to
the Phase I Unit,
No. (%)
Long Distance
to the Phase I Unit,
OR (95% CI)
Within the
workforce
33,790 (52.9) 1 (ref) 19,177 (48.6) 1 (ref) 63,590 (49.9) 1 (ref)
Outside the
workforce
30,122 (47.1) 0.73 (0.55 to 0.97) 20,244 (51.4) 0.83 (0.58 to 1.20) 63,891 (50.1) 0.70 (0.48 to 1.02)
Abbreviations: OR, odds ratio; ref, reference.
TABLE A7. Subgroup Analysis of ORs With 95% CIs For Referral to the Phase I Unit, Denmark, 2005 to 2016, by Children Living at Home (n 5 63,912
patients with short distance, n 5 39,421 patients with medium distance, and n 5 127,481 patients with long distance to Phase I Unit)
Children
Living at
Home
Short Distance to the
Phase I Unit, No. (%)
Short Distance to
the Phase I Unit, OR
(95% CI)
Medium Distance
to the Phase I
Unit, No. (%)
Medium Distance
to the Phase I Unit, OR
(95% CI)
Long Distance to the
Phase I Unit, No. (%)
Long Distance to the Phase
I Unit, OR (95% CI)
Yes 5,955 (9.3) 1 (ref) 2,429 (6.9) 1 (ref) 9,977 (7.8) 1 (ref)
No 57,957 (90.7) 1.53 (1.05 to 2.22) 36,692 (93.1) 0.76 (0.47 to 1.22) 117,504 (92.2) 0.76 (0.53 to 1.11)
Abbreviations: OR, odds ratio; ref, reference.
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